BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2015-05-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 735
- Registration Number
- NCT00446199
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 3449
- Registration Number
- NCT00440193
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2014-02-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4833
- Registration Number
- NCT00439777
Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-26
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1197
- Registration Number
- NCT00439725
Investigation of Mass Balance of the Test Drug and Major Metabolites
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 7
- Registration Number
- NCT00432302
Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 738
- Registration Number
- NCT00431678
Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2015-06-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 92
- Registration Number
- NCT00420342
Aerosolized Randomized Iloprost Study II (AIR - II) Long-Term Safety, Tolerability, and Clinical Effects of Iloprost Inhalation in Patients With Primary or Secondary Pulmonary Hypertension
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2009-05-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 63
- Registration Number
- NCT00414687
Use of Nebido® to Assess Tolerability and Treatment Outcomes in Daily Clinical Practice
- First Posted Date
- 2006-12-12
- Last Posted Date
- 2010-09-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1493
- Registration Number
- NCT00410306
Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 813
- Registration Number
- NCT00402727
© Copyright 2024. All Rights Reserved by MedPath